STOCK TITAN
  1. Home
  2. Sec-filings
  3. LCTX
  4. [SCHEDULE 13G/A] Lineage Cell Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Lineage Cell Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock LCTX logo
Lineage Cell The

NYSE:LCTX

LCTX Rankings

#3887 Ranked by Market Cap
N/A Ranked by Dividends

LCTX Latest News

Sep 2, 2025
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
Aug 26, 2025
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
Aug 12, 2025
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 5, 2025
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
Aug 4, 2025
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

LCTX Latest SEC Filings

Aug 26, 2025
[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event
Aug 15, 2025
[S-8] Lineage Cell Therapeutics, Inc. Employee Benefit Plan Registration
Aug 12, 2025
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event
Jul 3, 2025
[Form 4] Lineage Cell Therapeutics, Inc. Insider Trading Activity

LCTX Stock Data

274.03M
227.40M
0.42%
42.77%
11.93%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD